Insilico Medicine Launches Longevity Board for AI Drug Discovery
Cambridge, Massachusetts, USA, April 21, 2026 In a transformative step for AI-driven biotechnology and longevity science, Insilico Medicine has...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Cambridge, Massachusetts, USA, April 21, 2026 In a transformative step for AI-driven biotechnology and longevity science, Insilico Medicine has...
Hong Kong, April 6, 2026 Promising Results in Immunotherapy-Resistant NSCLC In a significant advancement for lung cancer immunotherapy, Akeso,...
NEW YORK, USA | March 24, 2026 Gilgamesh Pharma, a clinical-stage neuroscience company focused on next-generation neuropsychiatric therapeutics, has...
MALVERN, Pennsylvania, USA | March 24, 2026 In a major breakthrough for retinal disease treatment, Ocugen, Inc. has announced...
COPENHAGEN, Denmark, March 17, 2026 Ascendis Pharma A/S announced positive Week 52 topline results from its Phase 2 New...
THOUSAND OAKS, Calif., February 24, 2026 Amgen announced it will present at the 46th Annual TD Cowen Health Care...
VANCOUVER, Canada — December 4, 2025 — Renaissance BioScience Corp. announced that the Mexican patent office has granted a...
Tel Aviv — November 19, 2025 — Teva Pharmaceutical Industries Ltd. has launched Teva Rise, a groundbreaking global open-innovation...
Nanobiotix S.A. (Euronext: NANO, NASDAQ: NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches for cancer and other serious...
JACKSON CENTER, Pa., November 3, 2025 — Halberd Corporation, in collaboration with Mississippi State University (MSU), announced continued efforts...
